The biggest breakthroughs in mental health are on their way.
Be the first to know when Psilocybin-Assisted Psychotherapy becomes available through Journey Clinical.
For the millions still waiting for relief
Every person's depression is different. We're building the fullest range of options so more people can find the treatment that works best for them.
Treatment-resistant depression (TRD)
TRD is more than a diagnosis. It's the exhausting experience of trying treatment after treatment without lasting relief. An estimated 4 million people in the U.S. live with TRD, carrying longer depressive episodes, greater health risks, and a heavier toll on daily life. These are the people we serve, and the reason we believe science owes them new possibilities.
From clinical trials to your therapist's office
Journey Clinical is a research partner of Compass Pathways, whose investigational psilocybin treatment, COMP360, has now delivered positive results in two pivotal Phase 3 trials for treatment-resistant depression involving more than 1,000 participants. In both trials, many participants felt their symptoms lift quickly, sometimes within a day of treatment, and among those who responded, relief was held for six months or more after only one or two doses.
Outcomes like these are rare in TRD, a condition where new treatments have struggled for decades to demonstrate meaningful benefit. With Compass planning to complete its FDA submission later this year, psilocybin may be closer than it has ever been to becoming an approved treatment.
Early research suggests psilocybin may increase connectivity between brain regions that don't usually communicate, loosening rigid patterns in how we think about ourselves and relate to the world. Scientists believe this opens a period of heightened flexibility, a chance for the brain to build new pathways where old ones have kept people stuck.
Ready on day one
When psilocybin is approved, Journey Clinical will be ready. We operate the largest platform for FDA-approved psychedelic-assisted psychotherapy.
Our integrated psychiatry and psychotherapy model, with insurance-covered care, means patients won't have to navigate this new frontier alone. We also offer Spravato, which shows significant improvement in depression symptoms within 24 hours — and continues to demonstrate rapid improvement in symptoms at 4 weeks.
Be among the first
Psilocybin for treatment-resistant depression is on the horizon. Sign up today to be notified the moment it becomes available through Journey Clinical.